Feedback
Settings

Settings

Goto Application

92,776 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K33/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 9,278
1.WO/2026/102360METHODS AND COMPOSITIONS FOR CENTRAL NERVOUS SYSTEM (CNS) DRUG DELIVERY AND TREATMENT
WO - 15.05.2026
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/US2025/054709 Applicant UNIVERSITY OF MASSACHUSETTS Inventor SIRIANNI, Rachael
The disclosure herein provides, in example embodiments, methods and compositions for central nervous system (CNS) drug delivery and treatment comprising administering an infusion solution to a cerebrospinal fluid (CSF) of the subject, wherein the infusion solution comprises a hypertonic solution. The disclosure also provides compositions comprising a hypertonic solution for use in treatment and drug delivery in the CNS.
2.WO/2026/099190CALCIUM SILICATE PARTICLES FOR PHOSPHATE REDUCTION
WO - 15.05.2026
Int.Class C01B 33/24
CCHEMISTRY; METALLURGY
01INORGANIC CHEMISTRY
BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF
33Silicon; Compounds thereof
20Silicates
24Alkaline earth metal silicates
 Appl.No PCT/EP2025/081808 Applicant EVONIK OPERATIONS GMBH Inventor LUNDQUIST, Eric G.
The invention relates to calcium silicate particles comprising Tobermorite and characterized with a Ca/Si molar ratio of less than 0.7, a BET surface area greater than 50 m2/g, and CaO content of between 10 and 50 wt%. The invention further relates to the production thereof, and the use of calcium silicate particles for the removal of phosphate.
3.WO/2026/101994METHOD OF PRODUCING AND ADMINISTERING IMPROVED WOUND HEALING MODALITY
WO - 15.05.2026
Int.Class A61K 9/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
 Appl.No PCT/US2025/054149 Applicant ADVANCED HEALING TECHNOLOGIES, LLC Inventor ALCORN, Timothy
A treatment modality for use in the remediation of damaged tissues that involves protease down regulator solution impregnated microspheres, and the methods of production and therapeutic use thereof.
4.WO/2026/101090METHOD FOR PREPARING MAGNESIUM-SUBSTITUTED PRUSSIAN BLUE NANOPARTICLES, MAGNESIUM-PRUSSIAN BLUE NANOPARTICLES PREPARED THEREBY, AND USE THEREOF
WO - 15.05.2026
Int.Class A61K 9/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
 Appl.No PCT/KR2025/017308 Applicant KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY Inventor HAN, Hyung-Seop
The present invention relates to a method for preparing magnesium-substituted Prussian blue nanoparticles, and use thereof.
5.WO/2026/102005FORMULATION OF WOUND DRESSINGS AND THE USES THEREOF
WO - 15.05.2026
Int.Class A61K 33/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
38Silver; Compounds thereof
 Appl.No PCT/US2025/054165 Applicant IONIC PHARMACEUTICALS, LLC Inventor ARYAL, Shruti
The present disclosure provides a wound dressing and the uses thereof.
6.WO/2026/102020OPHTHALMIC SOLUTION CONTAINING QUATERNARY CHITOSAN DERIVATIVES FOR TREATING OCULAR DISEASES
WO - 15.05.2026
Int.Class A61K 31/722
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
716Glucans
722Chitin; Chitosan
 Appl.No PCT/US2025/054188 Applicant CLEARSIGHT THERAPEUTICS Inventor ACHARYA, Suchismita
A pharmaceutical composition to be applied to an ocular surface is disclosed that includes a quaternized chitosan derivative to provide antimicrobial activity against gram-negative bacteria, gram-positive bacteria, fungi, and viruses as an active ingredient. This is combined with a cellulose compound acting as a viscosity agent and demulcent to protect and lubricate mucous membrane surfaces. This is further combined with a humectant and tonicity agent to retain moisture on the ocular surface and maintain a comfortable osmolarity for the eye. This is further combined with a buffer/pH adjuster system configured to support a physiologically tolerable pH of about 6.0 to 8.0. Finally, this is combined with purified water as a diluent.
7.WO/2026/101464VIRUSES NEUTRALIZATION THROUGH A OXIDATION- REDUCTION REACTION ON THE VIRUS ENVELOPE
WO - 15.05.2026
Int.Class A61K 31/375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
375Ascorbic acid, i.e. vitamin C; Salts thereof
 Appl.No PCT/SK2025/000014 Applicant EUROPEAN INSTITUTE OF TECHNOLOGIES, S. R. O. Inventor TARASOV, Oleksandr
The name of the invention: "Neutralization of viruses through oxidation-reduction reaction on the virus envelope" suggests its use in medicine, both in the human and animal fields. This is not only a specific use, but also from the point of view of the dosage regimen, the method of dosage, a new group of patients, of component No. 1 - Cu2+ obtained in a solution of copper sulfate pentahydrate in distilled water, where copper must have at least two free ions and component No. 2 - L-ascorbic acid for neutralization of viruses through oxidation-reduction reaction on the virus envelope, which is characterized by the fact that it ensures the destruction of the virus envelope and thus the inhibition of viruses in humans and other warm-blooded animals. Both substances are administered in a non-toxic concentration appropriate for the human and animal organism and with an appropriate time interval, so that the most suitable conditions for the oxidation-reduction reaction on the virus envelope are created and maintained. The use of these two components establishes a scientifically proven premise for the successful prevention and treatment of infection with various types of enveloped viruses and the diseases they cause.
8.WO/2026/091196COMPOSITE COPPER SELENIDE-HALLOYSITE-MANNOSE DRUG DELIVERY SYSTEM, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 07.05.2026
Int.Class A61K 33/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
34Copper; Compounds thereof
 Appl.No PCT/CN2024/132994 Applicant SHANGHAI NORMAL UNIVERSITY Inventor NING, Congqin
Provided in the present invention is a composite copper selenide-halloysite-mannose drug delivery system. The drug delivery system comprises a carrier, wherein the carrier is halloysite nanotubes (HNTs), copper selenide (CuSe) nanoparticles are grown in situ on the walls of the halloysite nanotubes to form composite CuSe@HNTs, and mannose is loaded in the lumen of CuSe-coated HNTs to form composite drug delivery system CuSe@HNTs@ME. Further provided in the present invention are a method for preparing the composite copper selenide-halloysite-mannose drug delivery system, and the use thereof. The drug delivery system of the present invention can remain stable in a gastric acid environment and directly reach the site of enteritis by means of oral administration, thereby significantly alleviating the symptoms of enteritis.
9.20260124145LITHIUM SALT EXTENDED-RELEASE FORMULATIONS; METHODS OF MAKING; AND METHODS OF USE THEREOF
US - 07.05.2026
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No 19442284 Applicant Almatica Pharma LLC Inventor Ripal Gaudana

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.

10.WO/2026/094985TRANSDERMAL PREPARATION
WO - 07.05.2026
Int.Class A61K 47/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
02Inorganic compounds
 Appl.No PCT/JP2025/038106 Applicant NANOBEYOND CO., LTD. Inventor MORI, Masaki
The purpose of the present invention is to provide a transdermal preparation that makes it possible to enhance the efficacy of an active pharmaceutical ingredient to be transdermally administered.　This transdermal preparation contains an active pharmaceutical ingredient and carbonate apatite and has enhanced efficacy of the active pharmaceutical ingredient.
# -